Shivalik Rasayan Reports Q2 & H1 FY26 Results: Revenue Up, But Net Profit Declines Significantly
Shivalik Rasayan announced Q2 & H1 FY26 results. Revenue increased, but standalone and consolidated net profits for both the quarter and half-year significantly declined year-on-year, indicating profitability challenges.
The substantial decline in net profit, despite revenue growth, indicates pressure on profitability and could lead to a negative market reaction. Financial results are a key indicator of company performance.
Despite an increase in total income from operations, both standalone and consolidated net profits for the quarter and half-year ended September 30, 2025, showed a significant decline compared to the corresponding periods of the previous year.
The Board of Directors of Shivalik Rasayan Limited, in its meeting held on November 14, 2025, approved the Un-Audited Financial Results (Standalone and Consolidated) for the quarter and half year ended September 30, 2025. Key highlights of the financial performance are as follows: * Standalone Results (Quarter ended September 30, 2025 vs. September 30, 2024): * Total Income from Operations increased to ₹6,996.06 Lakhs from ₹6,079.96 Lakhs. * Net Profit for the period significantly decreased to ₹341.15 Lakhs from ₹1,386.69 Lakhs. * Standalone Results (Half Year ended September 30, 2025 vs. September 30, 2024): * Total Income from Operations increased to ₹13,770.18 Lakhs from ₹11,987.64 Lakhs. * Net Profit for the period decreased to ₹1,386.69 Lakhs from ₹2,042.25 Lakhs. * Consolidated Results (Quarter ended September 30, 2025 vs. September 30, 2024): * Total Income from Operations increased to ₹9,699.63 Lakhs from ₹8,497.64 Lakhs. * Net Profit for the period significantly decreased to ₹712.63 Lakhs from ₹2,042.25 Lakhs. * Consolidated Results (Half Year ended September 30, 2025 vs. September 30, 2024): * Total Income from Operations increased to ₹18,780.08 Lakhs from ₹16,571.75 Lakhs. * Net Profit for the period decreased to ₹2,042.25 Lakhs from ₹3,717.75 Lakhs. * The consolidated financial results include the Group's share of net profit after tax of ₹211.43 Lakhs for its associate, Medicamen Biotech Limited, for the quarter ended September 30, 2025. * The Board meeting commenced at 4:00 p.m. and concluded at 5:30 p.m. * The approved results, along with segment-wise revenue, assets, and liabilities, and the Limited Review Report, will be available on the company's website.
What to do with a filing like this
Shivalik Rasayan Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Shivalik Rasayan Limited. Read the original for the full detail.